ELPEN invests in Greece and creates value for the world
Published
The ELPEN Group is the largest Greek export-oriented pharmaceutical company. The company has approximately 2,000 employees and produces pharmaceutical products that are sold in many countries.
According to reports from HealthReport.gr, the ELPEN Group is investing in Greece while also seeking to create value at the international level. The company's export activity is important for the Greek economy, because it brings revenue into the country and shows that the Greek pharmaceutical industry can compete in international markets.
Investment in facilities, production and human capital in Greece is a key element of the Group's strategy. With its approximately 2,000 employees, ELPEN contributes to employment in Greece and to the development of local pharmaceutical manufacturing.
Overall, ELPEN's progress shows the role that a Greek company can play in the international pharmaceutical market. The article does not provide details about new investment plans or financial results, so developments should be followed through the company's future announcements.
Sources: HealthReport.gr
More Greece news
- The electric Renault 5 gains greater range and arrives in Greece with a special Roland-Garros edition
- Greece to contribute €120 million to European fund for high-tech companies
- Decline in technology and artificial intelligence stocks: How exposed are Greek companies?
- Meeting of Fidan and Güler on the cable across three capitals
- Interview Poll: New Democracy First with 29.4%, Ten Parties in Parliament
- Greece-Cyprus Cable: What Hatzidakis Said About France's License
- Conference on Access to Healthcare: Stelios Kymbouropoulos on the Today Press panel
- Georgia Parasxou at the Health Access Greece conference